AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. We do this by:
Leveraging our development and commercial expertise to invest in and grow our pharmaceutical products across a range of therapeutic areas, including women’s health
Actively sourcing new innovation in a variety of ways, including collaboration, partnership, and acquisition, identifying promising therapies in various stages of development and advancing them through the clinical and regulatory process to patients
Partnering with AMAG
Collaboration is one of our core values at AMAG. It influences who we are and how we operate and drives us to forge meaningful relationships with academic and research institutions, companies, and nonprofit associations with whom we can work together to meet unmet medical needs.
Additionally, our size and agility enables us to be flexible in our partnering structure and personalized in our deal-making, with every new collaborator and asset treated as high-value and high-priority.
Areas of Interest
Commercial success across our product portfolio has allowed us to expand our development capabilities and invest in promising therapies in a range of therapeutic areas. At present, we are particularly interested in products and platforms in fields such as hematology, supportive care, and women’s health.
Contact us about Partnering
To explore partnering opportunities with AMAG, contact our Business Development Team at email@example.com
Collaboration in Action
In 2017, licensed Vyleesi™, a novel investigational therapy for the treatment of low female sexual desire and associated distress, from Palatin Technologies, Inc. In June of 2018 the U.S. Food and Drug Administration (FDA) formally accepted our New Drug Application (NDA) for Vyleesi, which was supported by evidence from two large double-blind placebo-controlled Phase 3 clinical trials that found that it restored premenopausal women’s’ interest in sexual activity. Vyleesi is currently under review at the FDA, with anticipated approval and launch in 2019.